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Objectives: To evaluate the relationship between early changes in muscle and adipose tissue during che-
motherapy and overall survival (OS) in stage IV non-small cell lung cancer (NSCLC).
Materials and methods: In this post-hoc analysis of the ﬁrst line NVALT12 trial (NCT01171170) in stage IV
NSCLC, skeletal muscle (SM), radiation attenuation (RA), subcutaneous adipose tissue (SAT) and visceral adi-
pose tissue (VAT) were assessed at the third lumbar level on CT-images obtained before initiation of che-
motherapy and shortly after administration of the second cycle. The contribution of changes in diﬀerent body
compartments to overall survival was assessed.
Results: CT scans of 111 patients were included. Analysis of body composition changes between the baseline and
the follow-up scan, revealed that overall SM cross sectional area (CSA), radiation attenuation and SAT CSA
decreased respectively by −1.2 ± 2.9 cm2/m2 (p < 0.001), −0.7 ± 3.3 HU (p=0.026) and
−1.9 ± 8.7 cm2/m2 (p= 0.026), while no signiﬁcant changes in VAT tissue were observed. Longitudinally,
median OS was signiﬁcantly shorter among patients losing SM compared to patients with preserved SM (9.4
versus 14.2 months; HR 1.9, 95% CI: 1.23, 2.79, p= 0.003). Multivariate analyses showed that proportional loss
of muscle mass was associated with poor OS (HR 0.949, 95% CI: 0.915, 0.985, p= 0.006) independent from
important clinical prognostic factors including WHO-PS, gender, age and Charlson comorbidity index.
Conclusion: Early loss of SM during ﬁrst line chemotherapy is a poor prognostic factor in stage IV NSCLC pa-
tients. Future studies have to reveal whether early supportive intervention guided by initial CT muscle response
to chemotherapy can inﬂuence the wasting process and related mortality risk.
1. Introduction
Despite recent developments in cancer diagnostics and treatment
modalities, mortality rates maintain high in non-small cell lung cancer
(NSCLC) [1]. One of the factors contributing to high mortality rates is
progressive unintentional weight loss of body weight and muscle mass
(i.e. cachexia [2].
Computed tomography (CT) has emerged as a promising tool in
assessment of cancer cachexia. CT scans are routinely acquired in
cancer patients for disease diagnosis, staging and treatment follow-up
and thereby readily available from medical records to extract body
composition data. Skeletal muscle- and adipose tissue depletion, both
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characteristics of cachexia [3], are clinically important as predictors of
cancer outcomes [4–6]. Cachexia is frequently observed in lung cancer
[7] and low skeletal muscle mass at presentation has been linked to
functional deterioration, chemotherapy intolerance, and poor survival
rates [8–10].
Muscle tissue is plastic, undergoing constant remodelling in re-
sponse to anabolic and catabolic signals related to a.o. aging [11], ex-
ercise [12], malnutrition [13] inﬂammation [14] and drug interven-
tions [15]. Evidence from experimental research suggests that
chemotherapy might contribute to muscle wasting, via activation of
nuclear factor kappa B and upregulation of myostatin [16]. Thereby,
even weight stable patients with normal muscle mass before therapy
initiation might lose muscle mass during the course of treatment [17].
To date, a few longitudinal studies addressed changes in muscle
mass during anti-tumour therapy in NSCLC. In 35 stage IV NSCLC pa-
tients treated with palliative chemotherapy, muscle mass loss was ob-
served in half of the study population over the duration of che-
motherapy (approximately 9 weeks). However, the authors found no
signiﬁcant survival eﬀect in univariate analysis [18]. Another small
study reported muscle depletion in 30 stage III and IV NSCLC patients,
which was accompanied by physical functional decline. The prognostic
eﬀect of muscle depletion was not examined [19].
Next to skeletal muscle depletion, cachexia often also eﬀects other
tissues, including adipose tissue. Although adipose tissue mass has been
emerging as a prognostic factor, results to date are confusing. Patients
with low baseline subcutaneous adipose tissue in gastrointestinal- and
lung cancer [20] or low visceral adipose tissue in renal cell carcinoma
exhibited lower survival rates [21]. In contrast, high adipose inﬁltra-
tion in the skeletal muscle as a measure of muscle quality, reﬂected on
CT analysis by low skeletal muscle radiodensity, was associated with
shorter overall survival and shorter disease free survival in patients
with various other cancer types [5,22–25].
The prognostic value of early onset changes in muscle- and adipose
tissue compartments in therapy naïve NSCLC patients during che-
motherapy is lacking. Particularly, in this patient population known for
poor survival rates, timely information on body compartment changes
could be of clinical relevance for patient guidance and treatment de-
cision making. Therefore, the primary goal of our study is to evaluate
early body composition changes in relation to survival in therapy naïve
metastatic NSCLC patients undergoing chemotherapy.
2. Material and methods
2.1. Study population and study design
This study was a post-hoc analysis of a multicentre randomized
phase II trial investigating the eﬀect on survival of nitroglycerin patches
added to paclitaxel-carboplatin-bevacizumab in 223 therapy naïve pa-
tients with stage IV non-squamous NSCLC (NCT01171170). The full and
detailed methodology and results of this study has been published
previously [26].
In short, patients were randomized between paclitaxel-carboplatin-
bevacizumab with (experimental arm) and without nitroglycerin pat-
ches (control arm). Adding nitroglycerin to ﬁrst-line carboplatin-pa-
clitaxel-bevacizumab did not improve progression-free survival and
overall survival (OS) in patients with stage IV non-squamous NSCLC.
Exploratory endpoint of the study was to assess whether nitroglycerin
was related with an early decrease in 18 F-ﬂuorodeoxyglucose (18 F-
FDG) uptake. According to the protocol, a second 18 F-FDG positron
emission tomography (PET) scan combined with CT scan was assessed
for patients with a baseline PET/CT after the second cycle of che-
motherapy [27], with median follow-up time of 23 (17–50) days be-
tween follow-up scan and initiation of therapy. Speciﬁc patient char-
acteristics (age, gender, WHO PS, smoking status, histology, BMI and
Charlson comorbidity index) were selected from patient records [28].
Patients were selected from this study because the population is a well –
deﬁned randomized cohort in which all patients have received a
homogenous standardized chemotherapeutic regime. Next to this, all
patients were assessed by a physician with follow-up scans at pre-de-
termined time points.
2.2. Image analysis
In this post-hoc analysis body composition was analysed on low
dose CT scan by assessment of the cross-sectional area (CSA) at the third
lumbar level by two assessors. CSA of skeletal muscle, subcutaneous
adipose tissue and visceral adipose tissue were analysed with Slice-O-
Matic software v5.0 (Tomovision, Montreal, Canada). One image in
each scan was selected. During anatomical land marking, the ﬁrst image
at the third lumbar level with both vertebral transverse processes
clearly visible was used for analysis. CSA of these structures were
quantiﬁed based on pre-established thresholds of Hounsﬁeld units
(skeletal muscle -29 to 150, subcutaneous adipose tissue -190 to -30,
and visceral adipose tissue -150 to -50). Boundaries were corrected
manually when necessary.
Baseline CSA was normalised for height in meters squared and re-
ported in cm2/m2. Changes in CSA between CT scans were expressed as
a percentage. We found a mean coeﬃcient of variation between ob-
servers of 1.3% for skeletal muscle area, subcutaneous- and visceral
adipose tissue in a random sample of 15 patients, which is in line with a
variation of 0–2% in other studies [7,29–31]. Therefore, a measurement
error of 1.3% was adopted. Changes of equal or larger than −1.3%
were considered as ‘loss of tissue’, while changes of smaller than -1.3%
were considered ‘maintenance of tissue’. Furthermore, skeletal muscle
radiation attenuation was assessed as the average houseﬁeld units (HU)
of the total skeletal muscle area within the range -29 to 150 HU (i.e.
excluding intramuscular adipose tissue).
2.3. Study endpoints and statistical analyses
Patients were included if CT scans both at baseline and follow-up
were available, were assessed within 3 weeks after the second che-
motherapy and contained images of the third lumbar level. Descriptive
statistics of demographic and clinical variables were obtained. Means
(± SD) were provided for continuous normally distributed variables,
median (range) for continuous not-normally distributed variables and
percentages were shown for categorical variables. Comparisons within
groups were performed with paired t-test and between groups with an
independent t-test.
The primary endpoint of this study was OS. OS was deﬁned as the
interval from randomization to death from any cause. The probabilities
of OS were calculated using the Kaplan-Meier method. Survival curves
of patients with and without skeletal muscle loss were tested for sig-
niﬁcance using the log-rank test. To assess the contribution of diﬀerent
body compartments to OS, multivariate Cox regression analysis was
performed with body composition changes, gender, age, Charlson co-
morbidity index, and BMI as independent variables. Variables were
tested for interactions. In this study population the ECOG performance
score was between 0–1 in 97.5 percent of the patients and therefore not
included in the regression analysis. Proportional hazard assumption
was tested using visual inspection of log-minus-log survival plots. All
analyses were performed using SPSS statistical software (SPSS Statistics
for Windows, Version 24.0, IBM, Armonk, NY). Results with two-sided
exact p values (≤0.05) were considered statistically signiﬁcant.
3. Results
3.1. Patients and characteristics
CT scans from 111 of the 223 enrolled patients were eligible
(CONSORT Fig. 1). Baseline patient characteristics are shown in
Table 1.
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3.2. Body composition
Table 2 shows baseline measurements and body composition
changes parameters of the whole group. In total 65 (58.5%) lost muscle
mass during the course of chemotherapy. Analysis of body composition
changes between the baseline and the follow-up scan revealed that
muscle CSA, radiation attenuation and subcutaneous adipose tissue CSA
decreased respectively by -1.2 ± 2.9 cm2/m2 (p < 0.001), -0.7 ± 3.3
HU (p=0.026) and -1.9 ± 8.7 cm2/m2 (p= 0.026), while no sig-
niﬁcant changes in visceral adipose tissue were observed.
3.3. Survival
Median OS (95% conﬁdence interval [CI]) was similar between
subjects with normal versus low skeletal muscle index at baseline (12.2
months, 95% CI: 9.8, 14.7 versus 10.3 months, 95% CI: 7.8, 12.7, ha-
zard ratio 1.1, 95% CI: 0.8, 1.7, p= 0.496 [data not shown]).
Longitudinally, median OS was signiﬁcantly shorter among patients
losing skeletal muscle mass compared to patients with preserved ske-
letal muscle mass (9.4 months, 95% CI: 7.1, 11.6 versus 14.2 months,
95% CI: 11.3, 17.1, HR 1.9, 95% CI: 1.23, 2.79, p=0.003) (Fig. 2).
Multivariate analyses showed that proportional loss of muscle mass (HR
0.949, 95% CI: 0.915, 0.985, p=0.006) was associated with poor OS
independent from important clinical prognostic factors including WHO-
PS, gender, age and Charlson comorbidity index. (Table 3).
3.4. Adipose tissue compartments
On multivariate analysis, changes in skeletal muscle mass were as-
sociated with OS (Table 3). We therefore stratiﬁed patients in two
groups; ‘maintenance of skeletal muscle mass’ and ‘loss of skeletal
muscle mass’. At baseline, there were no diﬀerences between groups
regarding weight and body composition. Furthermore, groups did not
diﬀer in tumour progression (data not shown). Muscle loss was ac-
companied by a generalized loss of tissue as both subcutaneous fat and
visceral fat decreased. Furthermore, radiation attenuation decreased,
which could reﬂect gain in intramuscular fat (Table 4) [32].
4. Discussion
In the current study, we identiﬁed body composition changes after
two cycles of chemotherapy treatment initiation in stage IV NSCLC
patients. Skeletal muscle CSA, muscle radiation attenuation and to
lesser extent subcutaneous adipose tissue decreased throughout treat-
ment indicating a rapid loss in muscle mass and quality. Sixty-nine
percent of the patients lost muscle mass and exhibited worse survival
rates compared to those with preserved muscle mass.
Next to loss of muscle mass a rapid decline in skeletal muscle ra-
diation attenuation was observed during the course of treatment.
Reduced radiation attenuation is believed to reﬂect fat inﬁltration
(myosteatosis) in the muscle [33]. Myosteatosis in the muscle has in-
deed been observed in muscle biopsies from cancer patients and was
more aggravated in those with weight loss [34]. The phenomenon of
myosteatosis is shown in several patients groups including both obese
patients [35] and patients with low BMI. This suggests that high muscle
Fig. 1. Consort.
Table 1
Patient characteristics (N= 111).
Experimental arm/control arm, N 63 / 48
Male/Female, N 60 / 51
Age (mean, range) 61 (39, 79)
WHO – PS, N (%)
0 50 45.0)
1 46 (41.1)
2 3 (2.7)
Missing= 12
Pre-existent comorbidity, N (%)
COPD 16 (14.4)
Cardio - vascular 41 (36.9)
Diabetes Mellitus 12 (10.8)
Gastro - intestinal 15 (13.5)
> 1 co-morbidity 50 (45%)
Smoker, N (%)
Current 48 (43.2)
Ex 49 (44.1)
Never 14 (12.6)
Histology, N (%)
Adenocarcinoma 96 (86.5)
Large cell 6 (5.4)
Other 7 (6.4)
Missing= 2
Body weight, kg 74.1 ± 14.7
BMI, kg/m2 25.0 ± 4.3
Deﬁnition of abbreviations: WHO PS=World Health Organization
Performance Score.
BMI= body mass index.
Data are represented as mean ± SD or median (range), unless stated
otherwise.
Mutation status of the patients was not available.
J.H.R.J. Degens, et al. Lung Cancer 133 (2019) 130–135
132
fat inﬁltration is not merely a result of disturbed energy balance but
could be driven by disturbances in muscle oxidative metabolism.
A recent study, comparing changes in skeletal muscle during
treatment with chemotherapy or targeted therapy (EGFR or ALK TKI)
showed signiﬁcant diﬀerences in the loss of skeletal muscle in advanced
NSCLC patient [36]. Skeletal muscle was decreased in both groups, but
the loss of muscle mass was signiﬁcantly lower in the targeted therapy
group compared to chemotherapy.
In this study, all patients were treated with the same chemother-
apeutic regimen (carboplatinum, paclitaxel, bevacizumab). Therefore,
it is interesting to speculate about the inﬂuence of anti-cancer drugs
and toxicity on skeletal muscle changes in advanced NSCLC. From ex-
perimental research, it is known that chemotherapy can directly aﬀect
regulation of muscle maintenance, possibly mediated by NF-kB acti-
vation [37]. Cisplatin is known to induce NF-kB, which triggers muscle
wasting. In addition, also the tumour itself is able to increase NF-kB.
Thereby, muscle wasting might be both tumor- and chemotherapy in-
duced via common pathways mediated by NF-kB. In this study, nine-
teen (17%) of the patients experienced an adverse event graded with a
CTCAE of ≥ 3. There was no signiﬁcant diﬀerence in toxicity between
the group “muscle loss” and “muscle maintenance”. The underlying
mechanism why some patients experience chemotherapy-induced
muscle wasting, while others maintain muscle mass is unknown.
The added value of the current study is that also in patients re-
ceiving standardized chemotherapy, clinically relevant inter-individual
responses in body composition were observed (46 patients maintained
muscle mass and had a stable body weight) which may partly be re-
versible by early supportive interventions. Importantly in this context
and in contrast to some previous studies [4,6,9,10,25] we did not show
that low muscle mass and attenuation at baseline were prognostic for
overall survival.
The main strength of our study comes from the well-deﬁned ran-
domized patient cohort, receiving a standardized chemotherapeutic
regime [26]. However, this study is not without limitations. All patients
were treated with the same chemotherapeutic agents however in 63 of
111 patient nitroglycerine patches were added to the therapy. No dif-
ference in OS between the two groups was found [26]. The follow-up
CT scans were executed according to the protocol on predeﬁned times,
CT scans were performed in diﬀerent medical centres, whereby minor
variation in scanning procedure between hospitals and quality of the
images cannot be ruled out. Additionally, data on pre-treatment weight
Table 2
Body composition at baseline and change during therapy.
Baseline Change,
absolute
Change, percentage p value
change
Skeletal muscle CSA, cm2/m2 44.4 ± 6.9 −1.2 ± 2.9 −2.7 ± 6.6 <0.001
Radiation attenuation (HU) 31.5 ± 7.2 −0.7 ± 3.3 −1.9 ± 12.2 0.026
Subcutaneous adipose tissue CSA, cm2/m2 54.5 ± 31.8 −1.9 ± 8.7 −2.1 ± 20.2 0.026
Visceral adipose tissue CSA, cm2/m2 34.3 ± 22.5 0.6 ± 8.0 2.1 ± 29.3 0.438
Deﬁnition of abbreviations: CSA= cross-sectional area, HU=hounsﬁeld units.
Data are represented as mean ± SD.
Fig. 2. Kaplan Meier overall survival curve for patients with loss of muscle mass compared to patients without loss of muscle mass.
Table 3
Multivariate analysis for predictors of overall survival.
Variable Multivariate
HR 95% CI p value
Δ Muscle mass (%) 0.949 0.915, 0.985 0.006
Age (years) 1.008 0.978, 1,039 0.593
Gender 1.593 0.915, 2,772 0.100
WHO PS 1.084 0.847, 1.387 0.520
Charlson comorbidity index 1.132 0.960, 1.335 0.139
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loss were unavailable.
To conclude, this study shows prognostic value of body composition
changes after two cycles of chemotherapy treatment in stage IV NSCLC
patients. Therefore, CT derived assessment of body composition may
provide an additional tool for the treating physician to judge disease
severity and related prognosis. Future studies have to reveal whether
early supportive intervention, for example with intensive nutritional
support, guided by initial CT muscle response to chemotherapy can
inﬂuence the systemic consequences of NSCLC (treatment) and related
elevated mortality risk.
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